Unknown PHASE2 INTERVENTIONAL 9-arm NCT04355858

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Precision Treatment of Luminal Advanced Breast Cancer Based on Molecular Subtyping

Sponsor: Fudan University

Conditions Breast Cancer Metastatic Cancer

Interventions AI Capecitabine Everolimus Famitinib Nab paclitaxel Pyrotinib SERD SHR1210 SHR1701 SHR2554 SHR3162 SHR3680 SHR6390 SHR7390 VEGFi

Updated 7 times since 2020 Last updated: Jul 22, 2022 Started: May 1, 2020 Primary completion: May 1, 2023 Completion: Apr 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04355858, this PHASE2 trial focuses on Breast Cancer and Metastatic Cancer and remains ongoing. Sponsored by Fudan University, it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

May 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Nov 2021 — Sep 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jan 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China